← back to search

Ying‐Jun Chang

Peking University · CN
Area of research
Hematology · Immunology
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Immune Cell Function and Interaction, and Acute Lymphoblastic Leukemia research.
h-index
45
citations
7,397
works
516
NIH funding
primary concept
Medicine
email

Recent publications

Co-Mutation of ASXL1 and KRAS Defines a Novel Ultra-Adverse-Risk Subtype of Acute Myeloid Leukemia in a Large-Scale Cohort.
2026cited by 0position: contributordoi
Second alternative-donor haploidentical stem cell transplantation enhances survival in patients with myeloid malignancies complicated by posttransplant human leukocyte antigen loss relapse.
2026cited by 0position: contributordoi
Is sex chromosome loss a predictive marker for outcome after sex-mismatched allogeneic hematopoietic stem cell transplantation?
2026cited by 0position: contributordoi
Alternative donors, particularly haploidentical donors, are safe and effective for elderly patients with adverse-risk AML: a multicenter TROPHY study.
2026cited by 0position: contributordoi
Leukemia stem cells for relapse prediction in AML patients receiving allografts: long-term follow-up of a prospective study.
2025cited by 2position: contributordoi
Pretransplantation risk factors for positive MRD after allogeneic stem cell transplantation in AML patients: a prospective study.
2025cited by 2position: contributordoi
Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation.
2025cited by 1position: contributordoi
Impact of TP53 alteration on allogeneic hematopoietic cell transplantation outcomes for myelodysplastic syndromes.
2025cited by 1position: contributordoi
A New Risk Score System for Early Warning Gastrointestinal Graft-Versus-Host Disease Based on the Immune Function of Mucosal-Associated Invariant T Cells
Research Square 2025cited by 0position: middledoi
Eradicating measurable residual disease via immunotherapy to cure acute lymphoblastic leukemia: current status and future directions.
2025cited by 0position: contributordoi
Predictive strategies for poor outcomes after allotransplantation in patients with acute myeloid leukemia: what are the options and when should clinicians use them?
2025cited by 0position: contributordoi
Correction: Impact of TP53 alteration on allogeneic hematopoietic cell transplantation outcomes for myelodysplastic syndromes.
2025cited by 0position: contributordoi
Long-term survival in patients with Philadelphia-chromosome-positive acute lymphoblastic leukemia who relapse after allogeneic hematopoietic stem cell transplantation: a single-center experience.
2025cited by 0position: contributordoi
Prevalence, risk factors, and clinical impact of posttransplant anti-HLA antibodies after HLA-mismatched allografting: A multicenter prospective study
2025cited by 0position: contributordoi
Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience.
2024cited by 4position: contributordoi
Desensitization Strategies for Donor-Specific Antibodies in HLA-Mismatched Stem Cell Transplantation Recipients: What We Know and What We Do Not Know.
2024cited by 3position: contributordoi
Pretransplantation risk factors for MRD after allogeneic stem cell transplantation in AML patients: A prospective study
2024cited by 0position: contributordoi
An abnormality in the cerebrospinal fluid before transplantation is predictive of poor outcomes after allotransplantation in AML patients
2024cited by 0position: contributordoi
Cytology or Multiparameter Flow Cytometry Positivity in the Cerebrospinal Fluid Before Transplantation is Predictive of Poor Outcomes After Allotransplantation in Acute Myeloid Leukemia Patients.
2024cited by 0position: contributordoi
A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study
Science Bulletin 2023cited by 17position: middledoi
The adverse impact of ecotropic viral integration site-1 (EVI1) overexpression on the prognosis of acute myeloid leukemia with KMT2A gene rearrangement in different risk stratification subtypes.
2023cited by 3position: contributordoi
The impact of pre-transplant anti-HLA antibodies in transplants from HLA-identical sibling donors: a multicenter study
2023cited by 1position: contributordoi
Effects of CD34<sup>+</sup> cell dose on haematopoietic recovery in acute lymphoblastic leukaemia patients with positive pretransplant measurable residual disease.
2023cited by 1position: contributordoi
Salvage Haploidentical Transplantation for Graft Failure after First Haploidentical Allogeneic Stem Cell Transplantation: An Updated Experience
2023cited by 0position: contributordoi
An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study.
2022cited by 43position: contributordoi
Adoptive therapy with <scp>cytomegalovirus</scp>‐specific T cells for <scp>cytomegalovirus</scp> infection after haploidentical stem cell transplantation and factors affecting efficacy
American Journal of Hematology 2022cited by 34position: contributordoi
Prednisone plus IVIg compared with prednisone or IVIg for immune thrombocytopenia in pregnancy: a national retrospective cohort study
Therapeutic Advances in Hematology 2022cited by 15position: middledoi
Functional Competence of NK Cells via the KIR/MHC Class I Interaction Correlates with DNAM-1 Expression.
2022cited by 12position: contributordoi
Allogeneic hematopoietic stem cell transplantation for acute lymphoblastic leukemia: current status and future directions mainly focusing on a Chinese perspective.
2022cited by 3position: contributordoi
Cellular Immunotherapies for Multiple Myeloma: Current Status, Challenges, and Future Directions.
2022cited by 1position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 39 papers (2019–2026)Xiao‐Jun Huang · Lanzhou University27 papers (2016–2026)Yu Wang · Affiliated Hospital of Liaoning University of Traditional Chinese Medicine18 papers (2021–2026)Xiaohui Zhang · Capital Normal University18 papers (2016–2026) · 18 papers (2019–2026) · 18 papers (2021–2026) · 16 papers (2019–2026)Lan-Ping Xu · Peking University12 papers (2023–2026)Xiao‐Dong Mo · Peking University12 papers (2019–2026)Yuqian Sun · Lanzhou University9 papers (2020–2026)Xiao‐Su Zhao · Peking University People's Hospital, Peking University Institute of HematologyCollaborative Innovation Center of Hematology, Peking University8 papers (2019–2026) · 8 papers (2024–2026)Kai‐Yan Liu · South China Agricultural University5 papers (2019–2023)Ya‐Zhen Qin · Peking University4 papers (2022–2025)Qian Jiang · Nanjing University3 papers (2024–2026)Xiang-Yu Zhao · Elsevier, Inc.3 papers (2019–2022)Cheng Yifei · Springer Nature3 papers (2021–2025)Depei Wu · Soochow University2 papers (2020–2023)Cheng Li · Nanjing Medical University2 papers (2020–2021)Xiaoxia Hu · Guiyang Medical University2 papers (2023–2026)